Post hoc analyses of (FUTURE 5) 541 active PsA pts Rx w/ secukinumab shows NO radiographic progression through 2 years of SEC was assoc with achieving LDA at Week 104. https://t.co/ZeI9z4Civa https://t.co/LCI6kZ1z0v
Links:
Relationship of radiographic progression status to low disease activity in pati…
https://buff.ly/uAFMfD1
23-09-2025
